Glycaemic control in Type 2 diabetes - Not for sidelining

Diabetic Medicine

Volumn 25, Issue 6, 2008, Pages 639-642

  Narendran, P ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

ACCORD; ADVANCE; Glycaemic control; Type 2 diabetes

Indexed keywords

ACARBOSE; ANTIHYPERTENSIVE AGENT; FIBRINOLYTIC AGENT; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LIPID; METFORMIN;

ACUTE HEART INFARCTION; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTINUOUS INFUSION; DIABETIC RETINOPATHY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT CARE; PATIENT PARTICIPATION; POPULATION RESEARCH; QUALITY OF LIFE; REVIEW;

BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HUMANS; HYPOGLYCEMIA;

EID: 44649126674     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2008.02454.x     Document Type: Review

References (32)

1. National Prescribing Centre. Diabetes Type 2 Focussed Commentary. Available at http://www.npci.org.uk/therapeutics/cardio/diabetes2/ data_commentary/data_focussed_commentary1.php Last accessed 1 October 2007.
2. National Heart, Lung, and Blood Institute. For safety, NHLBI changes intensive blood sugar treatment strategy in clinical trial of diabetes and cardiovascular disease. Available at http://public.nhlbi.nih.gov/newsroom/home/ GetPressRelease.aspx?id=2551 Last accessed 6 February 2008.
3. Shechter M, Merz CN, Paul-Labrador MJ, Kaul S. Blood glucose and platelet-dependent thrombosis in patients with coronary artery disease. J Am Coll Cardiol 2000 35 : 300 307.
4. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993 16 : 434 444.
5. Zairis MN, Lyras AG, Makrygiannis SS, Psarogianni PK, Adamopoulou EN, Handanis SM et al. Type 2 diabetes and intravenous thrombolysis outcome in the setting of ST elevation myocardial infarction. Diabetes Care 2004 27 : 967 971.
6. Bakken AM, Palchik E, Hart JP, Rhodes JM, Saad WE, Davies MG. Impact of diabetes mellitus on outcomes of superficial femoral artery endoluminal interventions. J Vasc Surg 2007 46 : 946 958.
7. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998 352 : 837 853. Erratum in: Lancet 1999 354 : 602.
8. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998 317 : 703 713. Erratum in: BMJ 1999 318 : 29.
9. UK Prospective Diabetes Study (UKPDS) Group. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000 321 : 405 412.
10. Khaw KT, Wareham N, Luben R, Bingham S, Oakes S, Welch A et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European prospective investigation of cancer and nutrition (EPIC-Norfolk). BMJ 2001 322 : 15 18.
11. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998 352 : 854 865. Erratum in: Lancet 1998 352 : 1558.
12. Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 2004 25 : 10 16.
13. Stettler C, Allemann S, Jüni P, Cull CA, Holman RR, Egger M et al. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials. Am Heart J 2006 152 : 27 38.
14. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008 358 : 580 591.
15. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003 348 : 383 393.
16. http://www.nhlbi.nih.gov/health/prof/heart/other/accord/q_a.htm Last accessed 11 February 2008.
17. http://www.advance-trial.com/static/html/virtual/contents.asp?P=39 Last accessed 22 February 2008.
18. Abraira C, Colwell J, Nuttall F, Sawin CT, Henderson W, Comstock JP et al. Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes. Arch Intern Med 1997 157 : 181 188.
19. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000 23 (Suppl. 2 B21 29.
20. Linn T, Ortac K, Laube H, Federlin K. Intensive therapy in adult insulin-dependent diabetes mellitus is associated with improved insulin sensitivity and reserve: a randomized, controlled, prospective study over 5 years in newly diagnosed patients. Metabolism 1996 45 : 1508 1513.
21. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ et al Diabetes Control Complications Trial/Epidemiology of Diabetes Interventions Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005 353 : 2643 2653.
22. Ryan EA, Imes S, Wallace C. Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care 2004 27 : 1028 1032.
23. Li Y, Xu W, Liao Z, Yao B, Chen X, Huang Z et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function. Diabetes Care 2004 27 : 2597 2602.
24. Maedler K, Spinas GA, Lehmann R, Sergeev P, Weber M, Fontana A et al. Glucose induces beta-cell apoptosis via upregulation of the Fas receptor in human islets. Diabetes 2001 50 : 1683 1690.
25. DECODE study group on behalf of the European Diabetes Epidemiology Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999 354 : 617 621.
26. Malmberg K, Ryden L, Efendic S, Herlitz J, Nicol P, Waldenstrom A et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995 26 : 57 65.
27. Ingels C, Debaveye Y, Milants I, Buelens E, Peeraer A, Devriendt Y et al. Strict blood glucose control with insulin during intensive care after cardiac surgery: impact on 4-years survival, dependency on medical care, and quality-of-life. Eur Heart J 2006 27 : 2716 2724.
28. Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001 345 : 1359 1367.
29. Baker EH, Janaway CH, Philips BJ, Brennan AL, Baines DL, Wood DM et al. Hyperglycaemia is associated with poor outcomes in patients admitted to hospital with acute exacerbations of chronic obstructive pulmonary disease. Thorax 2006 61 : 284 289.
30. Taylor EP, Crawford JR, Gold AE. Design and development of a scale measuring fear of complications in type 1 diabetes. Diabetes Metab Res Rev 2005 21 : 264 270.
31. Lau C, Qureshi AK, Scott SG. Association between glycaemic control and quality of life in diabetes mellitus. J Postgrad Med 2004 50 : 189 194.
32. Gill GV, Woodward A, Pradhan S, Wallymahmed M, Groves T, English P et al. Intensified treatment of type 2 diabetes - positive effects on blood pressure, but not glycaemic control. QJM 2003 96 : 833 836.